[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629173":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":22,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":22,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":22,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":85,"whyStopped":22,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Biocells Medical","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Neuroinduced Mesenchymal Stem Cells","EXPERIMENTAL","200,000,000 neuroinduced mesenchymal stem cells administered via intravenous infusion.",[13],"Biological: Intrathecal (IT)",{"label":15,"type":10,"description":16,"interventionNames":17},"Mesenchymal Stem Cell Derived Exosomes","1×10¹¹ particles per infusion",[18],"Biological: Intravenous",{"label":20,"type":21,"description":22,"interventionNames":23},"Intravenous saline infusion","PLACEBO_COMPARATOR",null,[18],[25,30],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":22},"BIOLOGICAL","Intrathecal (IT)","Intrathecal injection of 3 ml between L4-L5",[9],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":22},"Intravenous","Intravenous injection via a drip",[20,15],[35],{"name":36,"role":37,"phone":38,"phoneExt":22,"email":39},"Andrei Peskau","CONTACT","+48452365311","info@biocellsmedical.com",[41],{"facility":42,"status":22,"city":43,"state":22,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Neuropostep","Warsaw","02-797","Poland","PL",{"type":48,"coordinates":49},"Point",[50,51],21.01178,52.22977,{"lat":51,"lon":50},[54],{"name":55,"role":37,"phone":56,"phoneExt":22,"email":39},"Anita Gerder","+48223074882",{"type":58,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100629173","phase-2-evaluation-of-neuroinduced-mesenchymal-stem-cells-and-mesenchymal-stem-cell-derived-exosomes-in-patients-with-parkinsonism-100629173",false,"NCT07471230","Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism","Phase II Randomized Controlled Trial Evaluating Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism","STEM-PARK","Inclusion Criteria:\n\nAge 40-80 years Clinical diagnosis of Parkinsonism Hoehn and Yahr stage II-III Stable pharmacological treatment for ≥3 months\n\nExclusion Criteria:\n\nAtypical parkinsonian syndromes unrelated to neurodegeneration History of malignancy within 5 years Severe cardiovascular disease Prior cellular therapy Active infection or immunosuppression","ALL","48 Years","70 Years",{"count":71,"type":72},120,"ESTIMATED","INTERVENTIONAL",[75],"PHASE2","This clinical trial investigates the safety and therapeutic potential of mesenchymal stem cell-based therapies in patients with parkinsonism.\n\nThe study evaluates neuroinduced mesenchymal stem cells and mesenchymal stem cell-derived exosomes as potential regenerative treatments targeting neurodegeneration within dopaminergic pathways.",[78,79],"Parkinsonism or Parkinson's Disease Nos","Parkinsonism in Diseases Classified Elsewhere",[81,82,83,84],"mesenchymal","exosomes","parkinsonism","stem cells","NOT_YET_RECRUITING","2026-03-10",{"date":88,"type":89},"2026-03-13","ACTUAL",{"date":91,"type":72},"2026-11-23",{"date":93,"type":72},"2029-11-23",{"name":5,"class":6},1]